Insights into medicinal attributes of imidazo[1,2-a]pyridine derivatives as anticancer agents

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Drug Discovery

Background:

• Cancer remains a leading global health threat, necessitating novel treatments with improved efficacy and reduced toxicity.
• Existing cancer therapies often face challenges like drug resistance and severe side effects.
• The imidazo[1,2-a]pyridine (IP) scaffold is a promising pharmacophore with diverse biological activities, including anticancer potential.

Purpose of the Study:

• To review and analyze the anticancer profiles of imidazo[1,2-a]pyridine derivatives developed between 2016 and the present.
• To highlight the structure-activity relationships (SARs) of these IP compounds.
• To underscore the therapeutic potential of the IP moiety in rational cancer drug design.

Main Methods:

• Literature review of synthesized IP derivatives with reported anticancer activity.
• Analysis of IP compounds targeting key cellular pathways: phosphoinositide-3-kinase/mammalian target of rapamycin (PI3K/mTOR), protein kinase B/mammalian target of rapamycin (Akt/mTOR), aldehyde dehydrogenase (ALDH), and tubulin polymerization.
• Evaluation of structure-activity relationships (SARs) to understand the impact of structural modifications on anticancer potency and selectivity.

Main Results:

• Numerous IP derivatives have demonstrated significant anticancer activity through various mechanisms.
• Specific substitution patterns on the IP core structure are crucial for modulating potency and targeting specific pathways.
• IP compounds show potential as inhibitors of PI3K/mTOR, Akt/mTOR, ALDH, and tubulin polymerization, offering targeted therapeutic strategies.

Conclusions:

• Imidazo[1,2-a]pyridine derivatives represent a valuable class of compounds for developing next-generation anticancer drugs.
• Further exploration of SARs can lead to the rational design of highly potent and selective IP-based anticancer agents.
• The IP scaffold holds considerable promise for future cancer therapeutics with potentially minimized toxicity.